New Market Study, "Czech Republic Pharmaceuticals & Healthcare Report Q4 2014", Has Been Published

Boston, MA -- (SBWIRE) -- 10/24/2014 -- The pharmaceutical supply chain within the Czech Republic has undergone a period of flux over the last decade. The pharmaceutical market itself, originally dominated by domestic and regional generic companies, has been won over by larger multinationals with competitive pressures expected to continue to favour those with scale. While we expect the Czech market to stabilise in 2014, we note that depreciatory pressure on the Czech koruna could see incomes decline for multinationals that operate within the Czech Republic. In addition, policies that regulate drug prices even further and reduce the cost of medicines to the state healthcare system and private insurers will weigh heavily on the growth prospects of the Czech pharmaceutical market, even as the Czech economy rebounds in 2015. Despite these concerns, BMI maintains a more optimistic long-term view. We believe that the need for innovative medicines will drive growth well above the rates of expansion achieved in Western Europe over our 10-year forecast period. In the longer term, the Czech Republic's disease and drug consumption profile illustrates a considerable gap between it and Western Europe, suggesting that the population's demand for high-value innovative medicines will continue until convergence.